Security key
98420X103
X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR)
CUSIP: 98420X103
Q1 2020 13F Holders as of 31 Mar 2020
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 11,262,165
- Total 13F value
- $112,618,520
- Share change
- +212,489
- SEC-reported price per share
- $10.00
- Number of holders
- 49
- Value change
- +$1,382,834
- Number of buys
- 24
- Number of sells
- 24
- Shares outstanding
- 94,372,096
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2020
Institutions
49
Top holders
10
XFOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420X103
Recent filing periods:
Ownership snapshot
Top reported holders of XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
31 Dec 2019
13F
Lead comparable stake: 1.7%
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 1.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Bain Capital Life Sciences Investors, LLC's linked filing trail.
Comparable ownership
Top 5
Bain Capital Life Sciences Invest...
1.7%
BVF INC/IL
1.2%
ORBIMED ADVISORS LLC
1.2%
FMR LLC
0.95%
BlackRock Finance, Inc.
0.85%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
1.7%
|
$17,639,000
1,648,485 shares
|
— | 31 Dec 2019 |
| BVF INC/IL |
13F
Company
|
1.2%
|
$12,219,000
1,141,974 shares
|
— | 31 Dec 2019 |
| ORBIMED ADVISORS LLC |
13F
Company
|
1.2%
|
$11,625,000
1,086,493 shares
|
— | 31 Dec 2019 |
| FMR LLC |
13F
Company
|
0.95%
|
$9,630,000
900,000 shares
|
— | 31 Dec 2019 |
| BlackRock Finance, Inc. |
13F
Company
|
0.85%
|
$8,554,000
799,579 shares
|
— | 31 Dec 2019 |
| VANGUARD GROUP INC |
13F
Company
|
0.76%
|
$7,711,000
720,686 shares
|
— | 31 Dec 2019 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
49
Shares
11,262,165
Rows available
49
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2020 vs Q4 2025 Across Filers
Q4 2025 holders
3
Q1 2020 holders
49
Holder diff
46
| Investor | Q4 2025 Shares | Q1 2020 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2020 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend